OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Biopharma looks to deliver on COVID-19 vaccines and other promising therapies.
Can lessons learned during the pandemic pay off in shorter development timelines?
J&J rollouts out initial vaccine supply; Industry expedites vaccine production
March 04, 2021
The European Medicines Agency and Health Canada have published clinical data used to support the authorization of Moderna’s COVID-19 vaccine.
The agency is working to identify and obstruct scammers looking to profit from the pandemic.
The European Medicines Agency has begun a rolling review based on laboratory and clinical studies of the Sputnik V (Gam-COVID-Vac).
The guidance document provides recommendations for reporting and implementing changes to container closure system components consisting of glass vials and stoppers for sterile drug products.
March 03, 2021
The EC has launched a structured dialogue aimed at gaining a better understanding of global medicines supply chains and to identify potential causes and drivers of vulnerabilities.
A recent survey by SwedenBIO has demonstrated a major upswing in the Swedish life science industry.
With funding from the federal government, Merck will expand capacity to produce J&J’s COVID-19 vaccine.
AstraZeneca has announced that the mass rollout of its COVID-19 vaccine has begun via the COVAX initiative.
March 02, 2021
Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.
In a pandemic, genetic vaccines offer several advantages over traditional approaches.
Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.
The need for real-time monitoring and control has spurred the development of new analytical tools.
March 01, 2021
Homology Medicines discusses how the clinical-stage biopharmaceutical company met its need for supply of adeno-associated virus vectors.
While manufacturing increases have been implemented for vials and syringes, meeting future market needs remains unpredictable.
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
The companies intend to design and implement algorithms for the early stages of research for drug discovery and development of drug candidates to treat Alzheimer’s disease.
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
The new ultra-sensitive second-generation micro-chip technology is a key enabler in advanced single-cell proteomics workflow.
Bio/pharma works hard today to change the calendar to tomorrow.
Through the acquisition, Merck will have access to Pandion’s pipeline of precision immune modulators targeting critical immune control nodes, including its lead candidate, PT101.
Through the partnership, Seven Bridges will centralize and manage terabytes of raw and processed scRNASeq data using its cloud-based bioinformatic analysis platform while working to expand Pfizer’s cloud platforms and capabilities.
Auditing distribution suppliers provides understanding and documentation of the services performed.
To prevent future production delays of critical products, the Biden administration is examining supply chain vulnerabilities for pharmaceutical ingredients as part of a longer-range consideration of products important to public health.
Distribution of the first one-dose vaccine for COVID-19 to start in early March.